Abstract
Over the last 10 years, Europe has witnessed the development of the ecstasy phenomenon; this term is used to describe several products sharing more or less the same effects. The most widely used and hence the most well known is 3,4 MDMA, but MDA, MDEA, MBDB and even 2CB or nexus are available. The psychopathological consequences of MDMA use in man are relatively poorly understood. The case reported here involves an acute psychotic episode with residual symptoms after six months, with a sudden onset at least 12 hours after taking alcohol and ecstasy without realising it, in an individual with no previous psychopathology other than a moderate anxiety disorder. Twelve cases of acute psychotic episodes after taking ecstasy have been reported in the literature; two after taking the drug on two occasions and one after a single use. No authors have examined the previous mental state or possible previous psychopathology with any precision. The present subject had not displayed any previous psychotic behavior when tested with a proven standardized interview technique; this was confirmed by his peers and his family. He did, however, show signs of social phobia. Although the personality of an individual is a factor in taking a drug, and p...Continue Reading
References
May 11, 1992·Annals of the New York Academy of Sciences·G A Ricaurte, U D McCann
Mar 23, 1991·BMJ : British Medical Journal·P McGuire, T Fahy
Nov 1, 1991·The American Journal of Psychiatry·K L DavisM Davidson
Nov 23, 1991·Lancet·F Schifano
Nov 1, 1991·The British Journal of Psychiatry : the Journal of Mental Science·F J CreightonC E Hyde
Jan 1, 1990·Annals of the New York Academy of Sciences·C J Schmidt, J H Kehne
Mar 18, 1988·JAMA : the Journal of the American Medical Association·K VerebeyJ H Jaffe
Sep 1, 1994·The British Journal of Psychiatry : the Journal of Mental Science·P K McGuireT A Fahy
Jan 1, 1993·Archives of General Psychiatry·E GouzoulisL Hermle
Apr 1, 1996·Clinical Neuropharmacology·M DemirkiranJ M Dean
Feb 1, 1996·Pharmacology, Biochemistry, and Behavior·L E Baker, M M Makhay
Oct 5, 1996·Lancet·E WebbF Kamali
Aug 1, 1996·Progress in Neurobiology·S R WhiteM J Wheaton
Mar 1, 1997·The Journal of Pathology·G N Rutty, C M Milroy
Aug 7, 1999·Journal of Psychoactive Drugs·A AlciatiC Mellado
Jan 1, 1994·Journal of Psychopharmacology·H SeriesR Peveler
Citations
Oct 31, 2002·Human Psychopharmacology·K. SoarA. C. Parrott
Nov 15, 2001·Current Psychiatry Reports·G O'LearyR D Weiss
Nov 2, 2006·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Maartje M L de WinWim van den Brink
Nov 24, 2004·Journal of Psychoactive Drugs·Robert S Gable
Aug 7, 2002·Journal of the American Academy of Child and Adolescent Psychiatry·Gabriele MasiChiara Floriani
Nov 21, 2012·Clinical Toxicology : the Official Journal of the American Academy of Clinical Toxicology and European Association of Poisons Centres and Clinical Toxicologists·Stephen L ThorntonRoy R Gerona
Apr 1, 2006·Journal of Psychopharmacology·K SoarA C Parrott
Sep 25, 2007·British Journal of Pharmacology·T MontgomeryG J McBean
Jun 17, 2020·Social Work in Public Health·Khary K Rigg, Alexandra Mills
Jun 5, 2004·CNS Drug Reviews·Roland W Freudenmann, Manfred Spitzer
May 26, 2018·Journal of Medical Case Reports·Kaeley KaplanKelly Serafini